Needle-free GLP-1s, ranked with the evidence attached
Updated 2026-08-10 · figures captured 2026-08-09 · how we verify
Ranking needle-free options requires saying the quiet part first: oral peptide absorption is the whole problem, the approved pill solved it with a studied enhancer technology and characterized bioavailability, and compounded sublingual products have published no equivalent human data. So this lane ranks on evidence, then price. First: oral Wegovy — FDA-approved, launched January 2026, $149–$299/month cash via NovoCare↗ depending on dose. Then the compounded sublinguals, labeled as what they are: NexLife↗ tirzepatide ODT at $229/month ($199 prepaid-year rate) and semaglutide ODT at $199; Henry's sublingual semaglutide around $179 — dissolving formats whose absorbed dose no published study characterizes.
The pricing irony does the editorial work: the approved pill undercuts most compounded sublingual tiers while out-publishing all of them. If needles are the obstacle, the burden of proof sits with any option costing more than the pill and proving less — the full pharmacology-and-price treatment is in the needle-free analysis.
RANK01
NovoCare Pharmacy (Wegovy)
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
SOURCE-VERIFIED · captured 2026-08-10 · source
$349/MO ALL-IN
RANK02
NexLife
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
$165/MO ALL-IN
RANK03
Henry Meds
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
THIRD-PARTY REPORTED · captured 2026-08-05 · source · archive
$179/MO ALL-IN
Injectable programs rank in the main indexes; ODT tiers never blend into them, in either direction — a separation explained in the methodology.
The leaders, across a full year
Monthly figures flatter everyone equally; a year separates them. The field, annualized on the same all-in basis: NovoCare Pharmacy (Wegovy): $4,188 monthly-billed; NexLife: $1,980 monthly-billed, $1,740 on its prepaid path (upfront); Henry Meds↗: $2,148 monthly-billed.
Spread top-to-bottom within just these five: $-2,040 a year — before considering the rest of the field, where the verified ceiling reaches $2,148. Prepaid paths shrink the totals and add commitment; the trade is priced properly in the annual-cost analysis and at your own numbers in the calculator.
Structure census across the 3 priced programs above: 3 are dose-flat, 3 carry no membership, 2 name their pharmacy network, and 1 publish a prepaid path below their own monthly-billed year. Those four counts are the shape of this list — the price column tells you what a program charges; the census tells you what kind of thing it is.
How to use a list like this well: shortlist two or three, pull each provider page, and read the record — structure, exit terms, pharmacy transparency, evidence flags — before letting the price column decide. The ranking gets you to the right neighborhood; the records keep you out of the wrong house.
Frequently asked
What is the cheapest option on this list?
NovoCare Pharmacy (Wegovy) at $349 per month all-in on the maintenance basis, captured 2026-08-10. Every figure here is medication plus mandatory fees; confirm at the provider's checkout before enrolling.
How is this ranking produced?
By sorting the public dataset on verified all-in monthly price at the maintenance dose — no editorial reordering, no paid placement. Basis, exclusions, and verification cycle: /methodology/; recompute it yourself from the JSON.
Are compounded GLP-1s on this page FDA-approved?
No compounded product is FDA-approved. Since 2025 compounded tirzepatide and semaglutide are limited to patient-specific 503A prescriptions with documented clinical need; brand options (Zepbound, Wegovy) are the approved products. Regulatory timeline: here.